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REPLY
We appreciate the comments made by Drs. Lin and Wright. The
essence of their letter seems to be that clarification of the
mechanisms whereby sulfonylurea drug use confers increased risk
could prove helpful in determining our best course of patient care.
We agree completely, but unfortunately available data are not yet
sufficient.
A sensible, although unproven, mechanistic explanation for
increased mortality during profound ischemia blames sulfonylurea
interference with K1ATP channel function. This action, as dem-
onstrated in many studies (1), impairs endogenous cardioprotective
mechanisms and may enhance arrhythmogenesis. In our study (2),
the cause of in-hospital mortality for sulfonylurea-treated patients
was chiefly cardiogenic shock plus a few arrhythmic deaths. We
sought a relation between sulfonylurea use and malignant arrhyth-
mias, but none was found, suggesting that any such effect must be
small relative to interference with other endogenous cardioprotec-
tive mechanisms. As noted in our report, however, mechanisms
other than interference with K1ATP channel function could
explain increased risk of death with sulfonylurea drug use.
Late all-cause and cardiac mortality rates were described in our
report, and, as expected, these patients died chiefly of cardiovas-
cular causes. Obviously, only hospital survivors were eligible for
continued monitoring, but it does not follow, as suggested by Drs.
Lin and Wright, that an early increased mortality risk would
necessarily translate into lower late risk for these patients. Indeed,
if the postulate regarding this class of drugs is correct, the survivors
continuing on sulfonylurea drugs may have been at continued
increased risk. However, it was not known how many survivors
continued taking sulfonylurea drugs after hospital discharge.
As Drs. Lin and Wright point out, our report is consistent with
a large body of indirect clinical evidence implicating sulfonylurea
drugs with increased risk. Alternative hypoglycemic drugs are
available, but existing data are not yet sufficient to make a blanket
recommendation to switch patients from sulfonylurea drugs.
Newer agents, such as the insulin-sensitizing thiazolidinediones
(e.g., troglitazone) and the biguanide compounds (e.g., metformin),
do not appear to have the deleterious cardiac properties of the
sulfonylurea drugs, but may cause other troubles: troglitazone may
cause significant hepatotoxicity and is not recommended as first-line
therapy (3), and metformin may cause lethal lactic acidosis, especially
in patients with renal insufficiency who are exposed to radiologic
contrast agents (4). Furthermore, many patients will require combined
drug therapy for optimal diabetic control (5).
More research is needed before a policy statement in this matter
can be justified. In this regard, corroboration of our findings from
larger data sets, data generated by several ongoing studies that
tabulate diabetic drug therapies and especially prospective studies
such as the planned Bypass Angioplasty Revascularization Inves-
tigation (BARI II) trial, will be of great importance.
We would be happy to support the work of Drs. Lin and Wright
by providing information on our patients that might be of use in
their meta-analysis.
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Risk of Sulfonylurea
Drugs Is Underappreciated
Garratt et al. (1) are to be congratulated on their excellent
retrospective study, which suggests that sulfonylurea hypoglycemic
drugs increase early mortality after direct angioplasty for acute
myocardial infarction. The data suggest that the increased mortal-
ity associated with the sulfonylurea drugs is due to pump dysfunc-
tion with cardiogenic shock. Unfortunately, the report does not
include a breakdown of the causes of in-hospital or late mortality.
One might predict that because early mortality was higher in the
sulfonylurea group, and these were presumably the higher risk
patients, late mortality would be less in this group. This predicted
decreased risk would be cancelled if the increased risk associated
with the sulfonylurea drugs continues, as is likely to be the case.
Other information that is missing from this study is when the
patients who died took their last dose of sulfonylurea and what
sulfonylurea drug they were taking. The most likely mechanism of
toxicity of the sulfonylureas drugs—abolishing ischemic precondi-
tioning through inhibition of the KATP channel—would require
the presence of a substantive amount of the drug at the time of the
myocardial infarction owing to recent intake or a long half-life of
the drug in the body.
This study provides further evidence that patients are dying
unnecessarily from use of a sulfonylurea drug. It supports the
findings of the randomized, controlled trials, such as the University
Group Diabetes Program (UGDP) Study (2,3) and the recently
published United Kingdom Prospective Diabetes Study (UKPDS)
(4,5). The UGDP study demonstrated increased cardiovascular
mortality in tolbutamide-treated patients as compared with those
who received placebo. The UKPDS trial showed a similar reduc-
tion of blood glucose with sulfonylurea drugs and metformin as
compared with diet, but there was no reduction in cardiovascular
events with sulfonylurea drugs (4) and a highly statistically signif-
icant reduction in cardiovascular events with metformin (5).
Therefore, there is substantial reason for exercising caution with
the prescription of sulfonylurea drugs to diabetic patients. We have
done a meta-analysis of studies of diabetic patients who had a
myocardial infarction and found that the chances of dying are
increased if the patient is taking a sulfonylurea drug versus
following a diet alone (unpublished data). If Garratt et al. (1) could
separate the group 2 patients into those treated with diet alone,
insulin or other hypoglycemic drugs, we could add their results to
our meta-analysis. These data, along with the other information
mentioned earlier, could be published in response to this letter.
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